Sensei Biotherapeutics, Inc.
SNSENASDAQHealthcare● Active
$13.00
$-1.65(-11.26%)
Market Cap$17445220
P/E Ratio—
52W High$36.76
52W Low$5.6
Sensei Biotherapeutics, Inc. (SNSE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SNSE · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$131.45
Est. -$0.62 · -21101.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS
SNSE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $3.50B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$3.50B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$3.37 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.62 | -$131.45 | -21101.6% | — | — | — |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$4.81 | -$3.74 | +22.3% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$4.11 | -$3.62 | +11.9% | $-0.00B | — | — |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$6.20 | -$3.91 | +36.9% | — | — | — |
| ▼ Q2 FY2025 | May 6, 2025 | -$4.20 | -$5.40 | -28.6% | — | — | — |
| — Q1 FY2025 | Mar 28, 2025 | -$5.40 | -$5.40 | +0.0% | — | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$6.20 | -$5.80 | +6.5% | — | — | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$3.37
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$131.45
EPS Est.
-$0.62
EPS Surpr.
-21101.6%
Revenue
—
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
-$3.74
EPS Est.
-$4.81
EPS Surpr.
+22.3%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$3.62
EPS Est.
-$4.11
EPS Surpr.
+11.9%
Revenue
$-0.00B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$3.91
EPS Est.
-$6.20
EPS Surpr.
+36.9%
Revenue
—
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$5.40
EPS Est.
-$4.20
EPS Surpr.
-28.6%
Revenue
—
Q1 FY2025
Mar 28, 2025
EPS Actual
-$5.40
EPS Est.
-$5.40
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$5.80
EPS Est.
-$6.20
EPS Surpr.
+6.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.88 | $-0.88 | $-0.88 | 1 |
| Q3 FY2027 | $-1.13 | $-1.13 | $-1.13 | 1 |
| Q2 FY2027 | $-1.08 | $-1.08 | $-1.08 | 1 |
| Q1 FY2027 | $-1.04 | $-1.04 | $-1.04 | 1 |
| Q4 FY2026 | $-1.88 | $-1.88 | $-1.88 | 1 |
| Q3 FY2026 | $-3.84 | $-3.84 | $-3.84 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -21101.6% | $19.82 | $20.43 | +3.08% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +22.3% | $27.68 | $25.13 | -9.21% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +11.9% | $9.02 | $8.01 | -11.20% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +36.9% | $8.65 | $8.24 | -4.74% |
| ▼ Q2 FY2025 | May 6, 2025 | -28.6% | $8.39 | $7.95 | -5.24% |
| ▲ Q1 FY2025 | Mar 28, 2025 | +0.0% | $8.62 | $10.17 | +17.98% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +6.5% | $10.63 | $9.24 | -13.08% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -12.0% | $12.20 | $13.00 | +6.56% |
Q2 FY2026+3.08%
Report Date
May 15, 2026
EPS Beat/Miss
-21101.6%
Price Before
$19.82
Price After
$20.43
Q1 FY2026-9.21%
Report Date
Mar 30, 2026
EPS Beat/Miss
+22.3%
Price Before
$27.68
Price After
$25.13
Q4 FY2025-11.20%
Report Date
Nov 14, 2025
EPS Beat/Miss
+11.9%
Price Before
$9.02
Price After
$8.01
Q3 FY2025-4.74%
Report Date
Aug 5, 2025
EPS Beat/Miss
+36.9%
Price Before
$8.65
Price After
$8.24
Q2 FY2025-5.24%
Report Date
May 6, 2025
EPS Beat/Miss
-28.6%
Price Before
$8.39
Price After
$7.95
Q1 FY2025+17.98%
Report Date
Mar 28, 2025
EPS Beat/Miss
+0.0%
Price Before
$8.62
Price After
$10.17
Q4 FY2024-13.08%
Report Date
Nov 14, 2024
EPS Beat/Miss
+6.5%
Price Before
$10.63
Price After
$9.24
Q3 FY2024+6.56%
Report Date
Aug 6, 2024
EPS Beat/Miss
-12.0%
Price Before
$12.20
Price After
$13.00
Avg Beat Reaction-4.05%
Avg Miss Reaction+1.47%
Beat Rate5 / 8 quarters
Largest Move+17.98% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SNSE ends December
Sensei Biotherapeutics, Inc. (SNSE) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-131.45 — missing the analyst consensus of $-0.62 by -21101.6%. The next SNSE earnings date is expected around September 1, 2026.
Each quarter, investors track SNSE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SNSE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SNSE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SNSE earnings · 5 questionsSensei Biotherapeutics, Inc.'s next earnings report is expected around September 1, 2026. SNSE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SNSE historically reports after market close (AMC).
SNSE earnings datewhen is SNSE earningsSNSE next earnings datewhen does SNSE report earningsSNSE earnings calendar
▸ Source: FMP · Sensei Biotherapeutics, Inc. SEC filings · US GAAP · Sensei Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026